menu
    • menu
    [{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"QT-019B","moa":"CD19|BCMA","graph1":"Immunology","graph2":"IND Enabling","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qihan Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Qihan Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Qihan Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CD33 CAR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qihan Biotech \/ Qihan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Qihan Biotech \/ Qihan Biotech"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Qihan Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QN-019a","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qihan Biotech \/ Qihan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Qihan Biotech \/ Qihan Biotech"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Qihan Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QN-023a","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qihan Biotech \/ Qihan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Qihan Biotech \/ Qihan Biotech"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Qihan Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QN-023a","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qihan Biotech \/ Qihan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Qihan Biotech \/ Qihan Biotech"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Qihan Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QN-030a","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qihan Biotech \/ Qihan Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Qihan Biotech \/ Qihan Biotech"},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Qihan Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qihan Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Qihan Biotech \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Qihan Biotech

    Menu

    Qihan Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QT-019B

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Clears IND For Qihan’s QT-019B Dual-Target CAR-T In Lupus

                            Details : QT-019B is an off-the-shelf allogeneic CAR-T cell therapy targeting CD19 and BCMA for the treatment of for refractory systemic lupus erythematosus.

                            Product Name : QT-019B

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 18, 2025

                            Lead Product(s) : QT-019B

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD33 CAR-NK Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Institute of Hematology & Blood Diseases Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

                            Details : CD33 CAR-NK Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 14, 2023

                            Lead Product(s) : CD33 CAR-NK Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Institute of Hematology & Blood Diseases Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-023a

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

                            Details : QN-023a is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 27, 2022

                            Lead Product(s) : QN-023a

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-030a

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natural Killer(NK) Cell Therapy in r/r AML

                            Details : QN-030a is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 27, 2022

                            Lead Product(s) : QN-030a

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-023a

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Institute of Hematology & Blood Diseases Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

                            Details : QN-023a is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 01, 2022

                            Lead Product(s) : QN-023a

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Institute of Hematology & Blood Diseases Hospital, China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-019a

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natural Killer (NK) Cell Therapy for B-Cell Malignancies

                            Details : QN-019a is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 18, 2022

                            Lead Product(s) : QN-019a

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Zhejiang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed

                            Qihan Biotech

                            China arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell T...

                            Details : Qihan will leverage its proprietary genome editing technology to reduce the immunogenicity of human stem cells, thus limiting their ability to provoke an immune response.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 14, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth